Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy

Michael N. Neely, Lorie Benning, Jiaao Xu, Howard Strickler, Ruth M. Greenblatt, Howard Minkoff, Mary Young, James Bremer, Alexandra M. Levine, Andrea Kovacs

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

BACKGROUND: Among women with low or undetectable quantities of HIV-1 RNA in plasma, factors associated with genital HIV-1 RNA shedding, including choice of treatment regimen, are poorly characterized. METHODS: We measured HIV-1 RNA in cervical swab specimens obtained from participants in the Women's Interagency HIV Study who had concurrent plasma viral RNA levels <500 copies/mL, and we assessed factors associated with genital HIV shedding. The study was powered to determine the relative effects of antiretroviral protease inhibitors (PIs) versus nonnucleoside reverse transcriptase inhibitors (NNRTIs) on viral RNA shedding. RESULTS: Overall, 44 (15%) of 290 women had detectable HIV-1 RNA in cervical specimens. In the final multivariate model, shedding was independently associated with NNRTI (vs. PI) use (odds ratio [OR], 95% confidence interval [CI]: 2.24, 1.13 to 4.45) and illicit drug use (OR, 95% CI: 2.41, 0.96 to 5.69). CONCLUSIONS: This is the largest study to define risks for genital HIV-1 RNA shedding in women with low/undetectable plasma virus. Shedding in this population was common, and NNRTI-based highly active antiretroviral therapy (HAART) (vs. PI-based HAART) was associated with genital HIV shedding. Further study is required to determine the impact of these findings on transmission of HIV from mother to child or to sexual partners.

Original languageEnglish (US)
Pages (from-to)38-42
Number of pages5
JournalJournal of Acquired Immune Deficiency Syndromes
Volume44
Issue number1
DOIs
StatePublished - Jan 2007

Fingerprint

Viremia
Highly Active Antiretroviral Therapy
HIV-1
Reverse Transcriptase Inhibitors
RNA
Protease Inhibitors
HIV
Viral RNA
Odds Ratio
Confidence Intervals
Virus Shedding
Sexual Partners
Street Drugs
Mothers
Viruses
Population

Keywords

  • Compartmentalization
  • Genital
  • HIV
  • Nonnucleoside reverse transcriptase inhibitor
  • Protease inhibitor
  • Undetectable
  • Viral replication
  • Women

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. / Neely, Michael N.; Benning, Lorie; Xu, Jiaao; Strickler, Howard; Greenblatt, Ruth M.; Minkoff, Howard; Young, Mary; Bremer, James; Levine, Alexandra M.; Kovacs, Andrea.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 44, No. 1, 01.2007, p. 38-42.

Research output: Contribution to journalArticle

Neely, Michael N. ; Benning, Lorie ; Xu, Jiaao ; Strickler, Howard ; Greenblatt, Ruth M. ; Minkoff, Howard ; Young, Mary ; Bremer, James ; Levine, Alexandra M. ; Kovacs, Andrea. / Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. In: Journal of Acquired Immune Deficiency Syndromes. 2007 ; Vol. 44, No. 1. pp. 38-42.
@article{9af9ee3a2800410cab68149cc9043b3f,
title = "Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy",
abstract = "BACKGROUND: Among women with low or undetectable quantities of HIV-1 RNA in plasma, factors associated with genital HIV-1 RNA shedding, including choice of treatment regimen, are poorly characterized. METHODS: We measured HIV-1 RNA in cervical swab specimens obtained from participants in the Women's Interagency HIV Study who had concurrent plasma viral RNA levels <500 copies/mL, and we assessed factors associated with genital HIV shedding. The study was powered to determine the relative effects of antiretroviral protease inhibitors (PIs) versus nonnucleoside reverse transcriptase inhibitors (NNRTIs) on viral RNA shedding. RESULTS: Overall, 44 (15{\%}) of 290 women had detectable HIV-1 RNA in cervical specimens. In the final multivariate model, shedding was independently associated with NNRTI (vs. PI) use (odds ratio [OR], 95{\%} confidence interval [CI]: 2.24, 1.13 to 4.45) and illicit drug use (OR, 95{\%} CI: 2.41, 0.96 to 5.69). CONCLUSIONS: This is the largest study to define risks for genital HIV-1 RNA shedding in women with low/undetectable plasma virus. Shedding in this population was common, and NNRTI-based highly active antiretroviral therapy (HAART) (vs. PI-based HAART) was associated with genital HIV shedding. Further study is required to determine the impact of these findings on transmission of HIV from mother to child or to sexual partners.",
keywords = "Compartmentalization, Genital, HIV, Nonnucleoside reverse transcriptase inhibitor, Protease inhibitor, Undetectable, Viral replication, Women",
author = "Neely, {Michael N.} and Lorie Benning and Jiaao Xu and Howard Strickler and Greenblatt, {Ruth M.} and Howard Minkoff and Mary Young and James Bremer and Levine, {Alexandra M.} and Andrea Kovacs",
year = "2007",
month = "1",
doi = "10.1097/01.qai.0000248352.18007.1f",
language = "English (US)",
volume = "44",
pages = "38--42",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy

AU - Neely, Michael N.

AU - Benning, Lorie

AU - Xu, Jiaao

AU - Strickler, Howard

AU - Greenblatt, Ruth M.

AU - Minkoff, Howard

AU - Young, Mary

AU - Bremer, James

AU - Levine, Alexandra M.

AU - Kovacs, Andrea

PY - 2007/1

Y1 - 2007/1

N2 - BACKGROUND: Among women with low or undetectable quantities of HIV-1 RNA in plasma, factors associated with genital HIV-1 RNA shedding, including choice of treatment regimen, are poorly characterized. METHODS: We measured HIV-1 RNA in cervical swab specimens obtained from participants in the Women's Interagency HIV Study who had concurrent plasma viral RNA levels <500 copies/mL, and we assessed factors associated with genital HIV shedding. The study was powered to determine the relative effects of antiretroviral protease inhibitors (PIs) versus nonnucleoside reverse transcriptase inhibitors (NNRTIs) on viral RNA shedding. RESULTS: Overall, 44 (15%) of 290 women had detectable HIV-1 RNA in cervical specimens. In the final multivariate model, shedding was independently associated with NNRTI (vs. PI) use (odds ratio [OR], 95% confidence interval [CI]: 2.24, 1.13 to 4.45) and illicit drug use (OR, 95% CI: 2.41, 0.96 to 5.69). CONCLUSIONS: This is the largest study to define risks for genital HIV-1 RNA shedding in women with low/undetectable plasma virus. Shedding in this population was common, and NNRTI-based highly active antiretroviral therapy (HAART) (vs. PI-based HAART) was associated with genital HIV shedding. Further study is required to determine the impact of these findings on transmission of HIV from mother to child or to sexual partners.

AB - BACKGROUND: Among women with low or undetectable quantities of HIV-1 RNA in plasma, factors associated with genital HIV-1 RNA shedding, including choice of treatment regimen, are poorly characterized. METHODS: We measured HIV-1 RNA in cervical swab specimens obtained from participants in the Women's Interagency HIV Study who had concurrent plasma viral RNA levels <500 copies/mL, and we assessed factors associated with genital HIV shedding. The study was powered to determine the relative effects of antiretroviral protease inhibitors (PIs) versus nonnucleoside reverse transcriptase inhibitors (NNRTIs) on viral RNA shedding. RESULTS: Overall, 44 (15%) of 290 women had detectable HIV-1 RNA in cervical specimens. In the final multivariate model, shedding was independently associated with NNRTI (vs. PI) use (odds ratio [OR], 95% confidence interval [CI]: 2.24, 1.13 to 4.45) and illicit drug use (OR, 95% CI: 2.41, 0.96 to 5.69). CONCLUSIONS: This is the largest study to define risks for genital HIV-1 RNA shedding in women with low/undetectable plasma virus. Shedding in this population was common, and NNRTI-based highly active antiretroviral therapy (HAART) (vs. PI-based HAART) was associated with genital HIV shedding. Further study is required to determine the impact of these findings on transmission of HIV from mother to child or to sexual partners.

KW - Compartmentalization

KW - Genital

KW - HIV

KW - Nonnucleoside reverse transcriptase inhibitor

KW - Protease inhibitor

KW - Undetectable

KW - Viral replication

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=33845967132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845967132&partnerID=8YFLogxK

U2 - 10.1097/01.qai.0000248352.18007.1f

DO - 10.1097/01.qai.0000248352.18007.1f

M3 - Article

C2 - 17106279

AN - SCOPUS:33845967132

VL - 44

SP - 38

EP - 42

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 1

ER -